AMPK Therapy—A Little Goes A Long Way

AMP-activated protein kinase (AMPK) is a highly conserved serine/threonine kinase that integrates energetic, nutrient, hormonal, redox, and stress signals to coordinate cellular and whole-body energy homeostasis. Although AMPK was initially characterized primarily as a sensor of changes in cellular AMP/ATP ratios, recent studies have revealed additional layers of regulation involving upstream kinases, post-translational modifications, heterotrimeric isoform composition, subcellular compartmentalization, and tissue-specific signaling. In this review, we provide an updated overview of the molecular mechanisms regulating AMPK activity, its major downstream metabolic and homeostatic pathways, its roles in metabolic, cardiovascular, neurodegenerative, muscular, malignant, and age-associated diseases, and current strategies for pharmacological AMPK modulation. We compare indirect activators, including metformin and naturally derived compounds, with direct small-molecule agonists targeting the allosteric drug and metabolite (ADaM) site, and emerging activators that selectively engage specific AMPK isoforms, tissues, or subcellular pools. We also discuss endogenous AMPK regulators, including microbiota-derived metabolites, and critically evaluate the potential adverse consequences of sustained or systemic AMPK activation. Collectively, current evidence indicates that the therapeutic effects of AMPK activation are highly dependent on tissue, heterotrimer composition, subcellular localization, disease stage, and the magnitude and duration of activation. Rather than indiscriminate systemic activation, future AMPK-directed therapies are therefore likely to benefit from isoform-, tissue-, and compartment-selective approaches that preferentially engage disease-relevant AMPK signaling while minimizing off-target effects. Continued characterization of AMPK signaling specificity and the development of selective pharmacological modulators should facilitate the translation of AMPK biology into more precise therapies for metabolic and other chronic diseases.

Authors

Institutions

Publication Details

Journal
Cells
Published
2026-08-20
DOI
https://doi.org/10.3390/cells15161503
Primary Topic
Metabolism, Diabetes, and Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

AMPK Therapy—A Little Goes A Long Way

Wendong Huang, Zhang Eryun, Hannah Ceballos
Cells
Metabolism, Diabetes, and Cancer
article

AMPK Therapy—A Little Goes A Long Way

Wendong Huang, Zhang Eryun, Hannah Ceballos
article en

Abstract

AMP-activated protein kinase (AMPK) is a highly conserved serine/threonine kinase that integrates energetic, nutrient, hormonal, redox, and stress signals to coordinate cellular and whole-body energy homeostasis. Although AMPK was initially characterized primarily as a sensor of changes in cellular AMP/ATP ratios, recent studies have revealed additional layers of regulation involving upstream kinases, post-translational modifications, heterotrimeric isoform composition, subcellular compartmentalization, and tissue-specific signaling. In this review, we provide an updated overview of the molecular mechanisms regulating AMPK activity, its major downstream metabolic and homeostatic pathways, its roles in metabolic, cardiovascular, neurodegenerative, muscular, malignant, and age-associated diseases, and current strategies for pharmacological AMPK modulation. We compare indirect activators, including metformin and naturally derived compounds, with direct small-molecule agonists targeting the allosteric drug and metabolite (ADaM) site, and emerging activators that selectively engage specific AMPK isoforms, tissues, or subcellular pools. We also discuss endogenous AMPK regulators, including microbiota-derived metabolites, and critically evaluate the potential adverse consequences of sustained or systemic AMPK activation. Collectively, current evidence indicates that the therapeutic effects of AMPK activation are highly dependent on tissue, heterotrimer composition, subcellular localization, disease stage, and the magnitude and duration of activation. Rather than indiscriminate systemic activation, future AMPK-directed therapies are therefore likely to benefit from isoform-, tissue-, and compartment-selective approaches that preferentially engage disease-relevant AMPK signaling while minimizing off-target effects. Continued characterization of AMPK signaling specificity and the development of selective pharmacological modulators should facilitate the translation of AMPK biology into more precise therapies for metabolic and other chronic diseases.

CellsVol. 15(16)
City Of Hope National Medical Center (US), City of Hope (US)
Reduced inequalities, Peace, Justice and strong institutions
Openalex Percentile: Top 16%
Metabolism, Diabetes, and Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.